News | Thrombectomy Devices | January 05, 2017

Global Thrombectomy Devices Market to Exceed $1 Million by 2022

Sedentary lifestyles, rise in geriatric population and demand for more minimally invasive treatments among factors driving market growth

global thrombectomy devices market, Allied Market Research report, 2022

January 5, 2017 — A new report published by Allied Market Research forecasts that the global thrombectomy devices market was valued at $982 million in 2016, and is expected to reach $1.389 million by 2022. This total will be supported by a compound annual growth rate (CAGR) of 5.9 percent during the forecast period 2014 to 2022. Mechanical thrombectomy would continue to be the preferred technology throughout the analysis period. North America dominated with around half of the market share in 2015 and is projected to maintain the lead throughout the forecast period.

High occurrences of acute myocardial infarction, peripheral artery disease, deep vein thrombosis, venous thromboembolism (VTE) and pulmonary embolism owing to sedentary and unhealthy lifestyles majorly drives the market growth, according to the report. VTE is most common in adults >60 years of age. In addition, better healthcare infrastructure and an increase in demand for minimally-invasive treatments; a rise in the geriatric population, which increases incidence of cardiovascular diseases; and technological advancements and innovations are the factors that nurture the growth of the thrombectomy devices market. Some of the restraints associated with the market are scarcity of trained professionals, lack of awareness and the complicated use of devices.

The disposable thrombectomy devices segment generated the highest revenue in 2015 and would continue to follow this trend throughout the analysis period.

Geographically, North America occupied a major market share in 2015, and is expected to continue leading during the analysis period. This was attributed to the sedentary and unhealthy lifestyle of the current generation, demand of better healthcare infrastructure, and increase in demand for minimally-invasive treatments and incidence of cardiovascular diseases. However, Asia-Pacific followed by LAMEA are expected to be the fastest growing regions, owing to the presence of ample growth opportunities in terms of unmet medical needs for the treatment of thrombus.

The thrombectomy devices market holds a substantial scope for growth globally. Recent innovations — which embed introduction of innovative ideas such as use of lasers, ultraviolet radiation and 3-D image generation — will provide better results to the physicians and allow them to work more efficiently. The upcoming trend in this market is the introduction of a technique that involves the combination of decompressive hemicraniectomy and endovascular thrombectomy to treat patients with cerebral venous thrombosis.

Among the other key findings were:

  • Neurovascular disorder is the major indication that uses thrombectomy devices for treatment; with over half of the total market share in 2015;
  • Peripheral and coronary diseases segments are projected to grow at a significant CAGR;
  • Reusable thrombectomy devices is projected to grow at a CAGR of 7.7 percent;
  • The U.S market for thrombectomy devices is projected to grow at a CAGR of 5 percent; and
  • The United States was the largest country market in 2015, and is projected to maintain its lead until 2022.

Key players have adopted mergers and acquisitions and product launch as their key strategies in the thrombectomy devices market. This is due to the growth in competition and continuous technological advancements. In July, 2016, Penumbra launched the ACE 68 Reperfusion Catheter for commercial use in the U.S. This catheter uses the latest tracking technology advancements available and delivers maximum aspiration power for extracting thrombus in stroke intervention. This product launch is expected to strengthen the product portfolio of Penumbra, a leading market player. The major market players profiled in this report include Boston Scientific Corp., Medtronic Plc, Teleflex Inc., Penumbra Inc., The Spectranetics Corp., AngioDynamics Inc., Terumo Corp., Johnson and Johnson Inc., Stryker Corp. and Vascular Solutions Inc.

For more information: www.alliedmarketresearch.com

Related Content

Abiomed, Impella heart pump, 50,000 patients treated, United States, milestone
News | Ventricular Assist Devices (VAD)| February 24, 2017
Abiomed Inc. announced that it has supported more than 50,000 patients in the U.S. with its Impella line of heart pumps...
coordinated heart attack care, Ontario STEMI Bypass Protocol, Canada
News | Cath Lab| February 22, 2017
Two new Ontario-wide heart attack protocols for paramedic services and emergency departments that aim to saves lives...
transradial approach, same-day cardiac procedures, radial access, $300 million annual savings, JACC Cardiovascular Interventions study
News | Radial Access| February 22, 2017
If hospitals can perform more transradial, same-day percutaneous coronary intervention (PCI), hospitals across the U.S...
Technology | Radial Access| February 17, 2017
Medtronic plc announced that its coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line...
Sponsored Content | Videos | Inventory Management| February 17, 2017
The supplies you use in your cath lab are complex and very valuable.
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Arterial Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
Cardinal Health survey, hospital staff, supply chain management, quality of care
News | Inventory Management| February 15, 2017
Better hospital supply chain management leads to better quality of care and supports patient safety, according to a new...
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders| February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Biotronik, PRO-Kinetic Energy cobalt chromium coronary stent system, FDA approval
Technology | Stents Bare Metal| February 15, 2017
The PRO-Kinetic Energy Cobalt Chromium (CoCr) Coronary Stent System from Biotronik has gained U.S. Food and Drug...
heart team, hybird OR, structural heart team

The heart team approach was first used on a large scale in the CoreValve and Sapien TAVR trials and helped lead to excellent outcomes in high-risk patients.

Feature | Hybrid OR| February 15, 2017 | Dave Fornell
In the current era of healthcare reform and the push toward evidence-based medicine to both lower costs and improve p
Overlay Init